Share on StockTwits

Fate Therapeutics (NASDAQ:FATE) issued its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.37) by $0.07, AmericanBankingNews.com reports.

Fate Therapeutics (NASDAQ:FATE) traded up 0.88% on Tuesday, hitting $6.00. 1,968 shares of the company’s stock traded hands. Fate Therapeutics has a 52 week low of $4.30 and a 52 week high of $13.55. The stock has a 50-day moving average of $6.31 and a 200-day moving average of $7.22. The company’s market cap is $123.1 million.

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

Receive News & Ratings for Fate Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.